Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
Inozyme Pharma is a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. We are experts in the PPi-Adenosine Pathway, where the ENPP1 enzyme generates inorganic pyrophosphate (PPi), which regulates mineralization, and adenosine, which controls intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels). Disruptions in this pathway impact the levels of these molecules, leading to severe musculoskeletal, cardiovascular, and neurological conditions, including ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL).BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 from 2:30-2:55pm ET.
波士頓，2024年11月27日（環球新聞社）--inozyme pharma公司（納斯達克：INZY）（「該公司」或「Inozyme」），一家臨床階段的生物製藥公司，在骨骼健康和血管功能受影響的罕見疾病領域開發創新治療藥物，今天宣佈，Inozyme的首席運營官兼高級副總裁Matt Winton博士將於2024年12月4日星期三美國東部時間下午2:30-2:55在派傑投資第36屆醫療保健年會上進行一場爐邊聊天。
A live webcast of the fireside chat can be accessed from the Investor Relations section of Inozyme's website under events, where a replay of the event will also be available for a limited time.
可以在Inozyme網站的投資者關係活動中訪問座談會的實時網絡廣播，活動的重播也將在有限時間內提供。
About Inozyme Pharma
關於Inozyme Pharma
Inozyme Pharma is a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. We are experts in the PPi-Adenosine Pathway, where the ENPP1 enzyme generates inorganic pyrophosphate (PPi), which regulates mineralization, and adenosine, which controls intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels). Disruptions in this pathway impact the levels of these molecules, leading to severe musculoskeletal, cardiovascular, and neurological conditions, including ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL).
inozyme pharma是一家開拓性的臨床階段生物製藥公司，致力於開發創新的治療方案，用於治療影響骨骼健康和血管功能的罕見疾病。我們是PPi-腺苷途徑的專家，其中ENPP1酶生成無機焦磷酸鹽（PPi），用於調節礦化，和腺苷，用於控制血管內膜增生（血管內平滑肌細胞的過度增長）。該途徑的紊亂會影響這些分子的水平，導致嚴重的肌骨骼，心血管和神經病症，包括ENPP1缺乏，ABCC6缺乏，鈣化性壞死和後縱韌帶骨化（OPLL）。
Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these molecules. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases.
我們的首席候選藥物INZ-701是一種ENPP1 Fc融合蛋白酶替代療法(ERT)，旨在增加PPi和腺苷，從而有可能治療由這些分子缺乏引起的多種疾病。目前，它正處於ENPP1缺陷、ABCC6缺陷和鈣磷病的臨床開發階段。通過靶向PPi-腺苷途徑，INZ-701旨在糾正病理性礦化和intimal增殖，從而應對這些毀滅性疾病中的重要發病率和死亡率問題。
For more information, please visit or follow Inozyme on LinkedIn, X, and Facebook.
如需更多信息，請訪問或關注Inozyme的LinkedIn、X和Facebook頁面。
Contacts
聯繫方式
Investors:
Inozyme Pharma
Stefan Riley, Senior Director of IR and Corporate Communications
(617) 461-2442
stefan.riley@inozyme.com
投資者:
inozyme pharma
IR和企業通訊高級董事Stefan Riley
(617) 461-2442
stefan.riley@inozyme.com
Media:
Biongage Communications
Todd Cooper
(617) 840-1637
todd@biongage.com
媒體:
Biongage通信-半導體
Todd Cooper
(617) 840-1637
todd@biongage.com
譯文內容由第三人軟體翻譯。
